Navigation Links
Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
Date:12/8/2009

NEW ORLEANS, Dec. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today an abstract to be published online at the journal Blood website by M. Hacker, et al. demonstrating significant reduction in cardiac cell toxicity with pixantrone compared to currently marketed anthracyclines. The authors conclude that the reduction is due to pixantrone's inability to generate toxic drug iron complexes and reduced propensity to generate oxygen free radicals. Pixantrone was specifically designed to have a higher affinity and avidity for the topisomerase II enzyme, which is the common target for this class of anti-cancer agents, while reducing oxygen-free radicals and preventing the formation of toxic drug metal complexes, which are the primary culprit that leads to dose-related irreversible heart damage associated with standard anthracyclines.

"This study adds to the growing scientific evidence which is central to the mechanistic basis for the relatively low incidence of cardiac events observed in our pixantrone clinical trials compared to the expected incidence of events had other anthracyclines been used. The ability to reintroduce an effective anthracycline like agent to patients who are no longer eligible to receive further standard anthracycline therapy due to potential irreversible heart damage addresses a major and growing unmet medical need," Jack Singer, M.D., Chief Medical Officer of Cell Therapeutics, Inc.

About the Study

To validate the proposed mechanisms underlying the observed differences in cardiotoxicity, researchers used established spectrophotometric techniques to quantify iron and drug interactions that are thought to be mechanistic for chronic doxorubicin cardiotoxicity. When adding increasing amounts of iron to drug solutions, they observed that doxorubicin and mitoxantrone underwent changes in visible range absorbance patterns, which is charact
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BD Ranked in the Top 100 Greenest Big Companies by Newsweek; Named Again to Dow Jones Sustainability World and North America Indexes
2. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
3. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
4. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
5. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
6. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
7. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
8. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
9. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
10. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
11. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 According to a ... of Material, Application (Healthcare, Homeland security, Industrial application, ... Instrument, Hand-Held Instruments, Fixed, and Installed Instruments) & ... published by MarketsandMarkets, the Scintillator Market is expected ... 2014 to 2020, and reach $479.16 Million in ...
(Date:7/11/2014)... -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: ... via a placement of A$16.3 million to institutional investors ... Asia and Australia ... (SPP) to be offered to existing shareholders.  The placement ... "This capital raising positions us strongly to ...
(Date:7/11/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) has ... Testing Market - Forecasts to 2019: Expected to ... is expected to be valued at USD 4,943.0 ... http://photos.prnewswire.com/prnh/20130307/600769 The ... according to immunoprotein types which include immunoglobulins, complement ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... , NEW YORK, ... market research report is available in its catalogue: ... Pharmaceuticals - Current and Future Market Outlook, Regulatory ... , Summary , The author ...
... , NEWNAN, ... specialty surface treatments for medical devices and of specialty implants, ... Gordy, will give an opening address for the Technology Parade ... Israel. "We must leave the era of petty self-interest ...
Cached Medicine Technology:Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 2Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 3Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 4Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 5Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 6Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 7Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 8CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices 2
(Date:7/14/2014)... (PRWEB) July 14, 2014 The governments ... investment in the Global Mobile Health Solutions market. For ... the Health IT for Economic and Clinical Health Act ... 2009. , Analysts forecast the Global Mobile Health ... 34.88 percent over the period 2013-2018. According to the ...
(Date:7/14/2014)... July 14, 2014 The report ... Services [Physical Security, Life Safety, Facility Management], IT ... Forecast & Analysis (2014 - 2019)” defines and ... an in-depth analysis and forecasting of revenues. The ... various restraints and opportunities impacting it, along with ...
(Date:7/14/2014)... fitness may buffer some of the adverse health effects ... by researchers from the American Cancer Society, The Cooper ... in the journal Mayo Clinic Proceeding s, and ... and blood markers associated with cardiovascular disease is markedly ... behavior has been linked to an increase risk of ...
(Date:7/14/2014)... 14, 2014 This report provides ... in Americas. The analysis includes market size data ... and key company share data by revenue in ... and Mexico. It uses data and information sourced ... in-house analysis. , Scope,     Information ...
(Date:7/14/2014)... 2014 Secure Decisions, a leading provider ... with the Software Assurance Marketplace (SWAMP) to build a ... that drives everyday life. , The SWAMP, implemented by ... the Morgridge Institute for Research, is funded by the ... security practices by building a free facility with a ...
Breaking Medicine News(10 mins):Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 2Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 3Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 4Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 3Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 4Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3
... and Willing to ... 20s, - Boomers Can Stay On-the-Go with New ThermaCare(R) Arthritis HeatWraps ... percent of baby boomers claim they feel an average of 11 ... they are more,adventurous and willing to experiment now than when they ...
... guided trial design may increase probability of tumor response ... and accelerates ... (Nasdaq and MTAX: CTIC) and Systems Medicine, LLC (SM), a,wholly-owned ... to its complete phase Ib trial of brostallicin used in ...
... CARLSBAD, Calif., Oct. 18 Isis,Pharmaceuticals, Inc. (Nasdaq: ... added a,new diabetes drug targeting the sodium dependent ... ISIS 388626, a generation 2.2,antisense drug that acts ... existing pipeline of drugs in development for the,treatment ...
... Lighted slippers for,those with troubled eyesight. A ... the player,s motions. Bowling equipment for those with ... One-stop online shopping for older adults and ... easier at Rehability! Your Optimal Living,Store, http://www.rehabilitystores.com ...
... Oct. 18 More than half of holiday shoppers ... to a good cause*. This,year, choose a gift that ... Alzheimer,s disease, the seventh leading cause of death,in the ... services for families struggling with,Alzheimer,s or support innovative research ...
... at US$26.00 Per Share -, VICTORIA, Oct. ... ; TSX: ASV) today announced that it has ... GALN) under which,Galenica, through a wholly-owned Canadian subsidiary, ... price of US$26.00 per share in cash. The,total ...
Cached Medicine News:Health News:Forget the 'Old' Stereotypes - New Survey Reveals that Baby Boomers Are Feeling More 'Young' and Active than Ever! 2Health News:Forget the 'Old' Stereotypes - New Survey Reveals that Baby Boomers Are Feeling More 'Young' and Active than Ever! 3Health News:Forget the 'Old' Stereotypes - New Survey Reveals that Baby Boomers Are Feeling More 'Young' and Active than Ever! 4Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 2Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 3Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 4Health News:Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes 2Health News:Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes 3Health News:Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes 4Health News:Holiday Gifts for Those With Disabilities & Other Special Needs 2Health News:Holiday Gifts That Help Fight Alzheimer's Disease 2Health News:Aspreva to be Acquired by Galenica For US$915 Million 2Health News:Aspreva to be Acquired by Galenica For US$915 Million 3Health News:Aspreva to be Acquired by Galenica For US$915 Million 4Health News:Aspreva to be Acquired by Galenica For US$915 Million 5
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... ThumbFit™ reduces joint instability without disturbing ... remarkably comfortable and easy for users ... CHT and Robert V. Sypher Jr., ... in response to patients' complaints of ...
... the MP joint and the CMC joint of the ... both of the thumb joints. An excellent choice for ... who need maximum mobility for daily activities. Ideal for ... and for those with pain due to repetitive stress. ...
... molded from rigid plastic in a distinctive design ... comfort. The uniquely sculpted distal trim line ... maximum function of the hand. This is ... and sprains of the MCP joint, basal joint ...
Medicine Products: